|
TLA Buster
Tired of TLAs (Three letter acronyms)? Try seaching on
the acronym buster
|
| |
|
Previous NSEP Event
What Investors in Pharma and Biotech are looking for
And how to meet those expectations
Tuesday 1st March 2005, Four Seasons Hotel, London, 18.30
Event timing
The event starts at 6.30pm. The short talks and panel discussions last approximately 1¼ hours and will be followed by cocktails and
canapés - the ideal networking opportunity. We are delighted that this networking evening will be held at the world famous Four Seasons Hotel, one of the most prestigious venues in the country.
About the event
With investors shying away from big Pharma at the moment, is this a golden opportunity for
Biotech to increase their share of the pot or is it a temporary blip which will result in investors
rushing back into big Pharma's (welcoming) arms? The big question is "what are the investors looking for?".
Is it security, growth or a mixture of both and how should Biotech and Pharma companies respond to those demands?
This event will try to look at the problem from both sides: what the management should do to
keep investors on board and what the stakeholders can reasonably expect of the management and
their options should they not achieve those expectations.
In particular the following issues will be examined:
- The extent to which people are investing in Biotech and Pharma and how this affects the expectations of other shareholders
- Why pharmaceutical and biotech stocks will outperform the market in the long run and how to communicate this
- How does M&A affect the shareholder value in the industry?
- The different expectations of the institutional and private investors
- Which companies offer the best investment potential - large, medium or small caps?
- How investors spot winners
- How management can demonstrate that their projects are winners
- When should shareholders call time on management and how management should guard against this
- Does the market need more corporate information and if so how to deliver this information
- What management should do if it thinks that the share price is too low (or too high)
Networking evening
One of the main reasons to attend this event is the opportunity to meet other key players within the industry,
whether they be CEOs, Finance Directors, other key Directors, Consultants, Lawyers etc. Due to the nature of
this event NSEP will be particularly targeting the investors, including venture capitalists, banks, fund
managers and corporate financial advisors.
The cocktail party immediately following the event (it is almost worth coming for the famous Four
Seasons canapés themselves!) is the ideal place to discuss matters in a less formal environment, whether
this discussion is directly related to the event topic or not.
Outstanding speaker panel
Dr John Court - CEO FULCRUM
Dr Court is a founder of Fulcrum and has been CEO since the company was established.
As CEO, he is responsible for driving the strategic direction of the Group and ensuring
high standards of management to maximise benefits to customers, shareholders and employees.
Prior to establishing Fulcrum, Dr Court was Managing Director and a Board member of Protodigm Limited,
a wholly owned subsidiary of the large pharmaceutical company Roche. He was responsible for establishing
the company and assembling the management team. In the three years of operating Protodigm as a virtual
drug development company, Dr Court and the management team developed the supplier contacts, skills
and processes necessary to develop drugs in a virtual environment with significant speed and cost
savings against industry benchmarks.
Previously, Dr Court was head of Project Management for Roche in the UK, having led the development of
Invirase from discovery through to global registration in less than 5 years, which was recognised by the
1995 UK Prix Galien for Research and in 1999 by the International Prix Galien. Prior to Roche, Dr Court
held scientific and management positions at Wellcome Plc. Dr Court holds a PhD in Parasitology and
Immunology from Salford University.
Jan Lundberg - Executive Vice President ASTRAZENECA
Jan has an extensive research experience. He was previously Senior Vice President, Head of Global Discovery, a position he had since the Astra-Zeneca merger in 1999. Before the merger, Jan was Head of Preclinical Affairs, Astra AB, with responsibilities for Discovery build up of enabling technologies, project co-ordination and evaluation.
Jan has a medical education from University of Gothenburg and was a professor at the Department of Pharmacology at the Karolinska Institute in Stockholm before joining Astra AB. He has published more than 500 scientific articles, mainly related to mechanisms of cell signalling in the nervous-, cardiovascular-, and respiratory systems. Jan has won a variety of research awards and he is a highly cited author on www.isihighlycited.com in the areas of Biology & Biochemistry, Pharmacology and Neuroscience.
Patrick Lee - Partner ADVENT VENTURES
Patrick has a well-established commercial and transactions track record in healthcare, pharmaceuticals
and medical products. After gaining a BA in biology from Vassar and an MBA from Stanford, Patrick worked
with management consultancy Booz Allen & Hamilton and then Baxter International. He was Group Vice President
for mergers & acquisitions at Rhône Poulenc in Paris prior to joining Advent. His responsibilities at Rhône
Poulenc included transactions with established and emerging companies worth over $40 billion as well as
general management.
Since joining Advent he has developed investment opportunities in pharmaceutical, healthcare and medical
devices businesses, in various stages of their development.
Who will attend?Expected breakdown of job
titles
Expected breakdown by
audience sector
© NSEP 2007 -
All rights reserved
|
|